52 related articles for article (PubMed ID: 10146934)
1. Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy.
Faunce T; Doran E; Henry D; Drahos P; Searles A; Pekarsky B; Neville W
Global Health; 2005 Oct; 1():15. PubMed ID: 16209703
[TBL] [Abstract][Full Text] [Related]
2. Clinical guidelines, the politics of value, and the practice of medicine: physicians at the crossroads.
Cooper RA; Straus DJ
J Oncol Pract; 2012 Jul; 8(4):233-5. PubMed ID: 23180988
[TBL] [Abstract][Full Text] [Related]
3. Toward a treaty on safety and cost-effectiveness of pharmaceuticals and medical devices: enhancing an endangered global public good.
Faunce TA
Global Health; 2006 Mar; 2():5. PubMed ID: 16569240
[TBL] [Abstract][Full Text] [Related]
4. The emerging government requirement for economic evaluation of pharmaceuticals.
Drummond M
Pharmacoeconomics; 1994; 6 Suppl 1():42-50. PubMed ID: 10155586
[TBL] [Abstract][Full Text] [Related]
5. The role of pharmacoeconomics in health policy and management in Norway.
Grund J; Husbyn H
Pharmacoeconomics; 1995 Jun; 7(6):475-83. PubMed ID: 10155333
[No Abstract] [Full Text] [Related]
6. Cost-effectiveness analysis: obstacles to standardisation and its use in regulating pharmaceuticals.
Luce BR
Pharmacoeconomics; 1993 Jan; 3(1):1-9. PubMed ID: 10146982
[No Abstract] [Full Text] [Related]
7. The reimbursement factor in pharmaceutical regulation: rebates, cost-effectiveness, and practice guidelines.
Shulman SR
Pharmacoeconomics; 1992; 1(Suppl 1):21-7. PubMed ID: 10146927
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of pharmaceuticals: a European perspective.
Drummond M; Rutten F; Brenna A; Pinto CG; Horisberger B; Jönsson B; Le Pen C; Rovira J; von der Schulenburg MG; Sintonen H
Pharmacoeconomics; 1993 Sep; 4(3):173-86. PubMed ID: 10146921
[TBL] [Abstract][Full Text] [Related]
9. Is there a need for an independent centre for pharmacoeconomics in the UK?
Walley T; Edwards RT
Pharmacoeconomics; 1994 Feb; 5(2):93-100. PubMed ID: 10146902
[No Abstract] [Full Text] [Related]
10. Assessment of medical technology: the role of engineers.
Hutton J
Med Biol Eng Comput; 1993 Jan; 31(1):HTA11-5. PubMed ID: 8326751
[TBL] [Abstract][Full Text] [Related]
11. Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals.
Henry D
Pharmacoeconomics; 1992 Jan; 1(1):54-67. PubMed ID: 10147039
[TBL] [Abstract][Full Text] [Related]
12. The subsidy of pharmaceuticals in Australia: processes and challenges.
Sansom L
Aust Health Rev; 2004 Nov; 28(2):194-205. PubMed ID: 15527399
[TBL] [Abstract][Full Text] [Related]
13. Evidence-based decision on medical technologies in Asia Pacific: experiences from India, Malaysia, Philippines, and Pakistan.
Thatte U; Hussain S; de Rosas-Valera M; Malik MA
Value Health; 2009; 12 Suppl 3():S18-25. PubMed ID: 20586975
[TBL] [Abstract][Full Text] [Related]
14. Are the economics of pharmaceutical research and development changing?: productivity, patents and political pressures.
Grabowski H
Pharmacoeconomics; 2004; 22(2 Suppl 2):15-24. PubMed ID: 15660474
[TBL] [Abstract][Full Text] [Related]
15. Australian guidelines for cost-effectiveness studies of pharmaceuticals: the thin end of the boomerang?
Drummond M
Pharmacoeconomics; 1992; 1(Suppl 1):61-9. PubMed ID: 10146934
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness guidelines. The experience of Australian manufacturers.
Gorham P
Pharmacoeconomics; 1995 Nov; 8(5):369-73. PubMed ID: 10160071
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
